{"id":"infusional-5-fluorouracil","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hand-foot syndrome"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Mucositis"}]},"_chembl":{"chemblId":"CHEMBL185","moleculeType":"Small molecule","molecularWeight":"130.08"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"5-Fluorouracil works by inhibiting thymidylate synthase, an enzyme involved in DNA synthesis, thereby preventing cancer cell growth.","oneSentence":"Inhibits thymidylate synthase","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:36:26.156Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer"}]},"trialDetails":[{"nctId":"NCT04495088","phase":"PHASE3","title":"Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Ralf Hofheinz","startDate":"2020-09-30","conditions":"Rectal Cancer","enrollment":550},{"nctId":"NCT04165772","phase":"PHASE2","title":"Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-12-11","conditions":"Rectal Adenocarcinoma, Clinical Stage: Stage II (T3-4, N-), Stage III (Any T, N+)","enrollment":200},{"nctId":"NCT06205485","phase":"PHASE3","title":"Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2024-06-26","conditions":"Rectal Cancer","enrollment":250},{"nctId":"NCT07267806","phase":"PHASE3","title":"Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC","status":"RECRUITING","sponsor":"Linhui Peng","startDate":"2025-10-31","conditions":"Hepato Cellular Carcinoma (HCC), Chemotherapy Effect","enrollment":326},{"nctId":"NCT06172205","phase":"PHASE3","title":"Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-07-01","conditions":"BCLC Stage C Hepatocellular Carcinoma, Chemotherapy Effect","enrollment":262},{"nctId":"NCT06632717","phase":"PHASE2","title":"Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-09-01","conditions":"Hepatocellular Carcinoma","enrollment":24},{"nctId":"NCT05780684","phase":"NA","title":"Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2023-07-14","conditions":"Colorectal Cancer, Esophagus Cancer, Appendix Cancer","enrollment":36},{"nctId":"NCT05329103","phase":"PHASE1","title":"A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Peel Therapeutics Inc","startDate":"2022-07-11","conditions":"Advanced Solid Tumor","enrollment":65},{"nctId":"NCT05141721","phase":"PHASE2, PHASE3","title":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seattle Project Corporation","startDate":"2022-02-12","conditions":"Colorectal Neoplasms","enrollment":700},{"nctId":"NCT05004350","phase":"PHASE2","title":"A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2021-09-14","conditions":"BRAF V600E, Metastatic Colorectal Cancer","enrollment":107},{"nctId":"NCT04920032","phase":"PHASE1","title":"Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2021-08-26","conditions":"Colon Adenocarcinoma, Colorectal Cancer","enrollment":22},{"nctId":"NCT03597581","phase":"PHASE1","title":"A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Inspirna, Inc.","startDate":"2018-06-05","conditions":"Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer","enrollment":89},{"nctId":"NCT02572141","phase":"PHASE3","title":"FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2015-01-01","conditions":"Colon Cancer","enrollment":738},{"nctId":"NCT01924819","phase":"PHASE2, PHASE3","title":"Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2009-09","conditions":"Gastric Cancer","enrollment":574},{"nctId":"NCT04375605","phase":"PHASE3","title":"Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitätsmedizin Mannheim","startDate":"2020-06-03","conditions":"Gastroesophageal Junction Adenocarcinoma","enrollment":342},{"nctId":"NCT06538610","phase":"NA","title":"The 5-FU Holter Study","status":"RECRUITING","sponsor":"University of Auckland, New Zealand","startDate":"2024-11-01","conditions":"Gastrointestinal Malignancy","enrollment":10},{"nctId":"NCT02199236","phase":"PHASE1","title":"Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-07","conditions":"Rectal or Anal Cancer","enrollment":15},{"nctId":"NCT04456699","phase":"PHASE3","title":"Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-19","conditions":"Metastatic Colorectal Cancer","enrollment":335},{"nctId":"NCT04547153","phase":"PHASE2","title":"Infusional Fluorouracil and Weekly Docetaxel for Gastric Cancer With Bone Marrow Involvement and DIC","status":"COMPLETED","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2021-01-15","conditions":"Gastric Cancer, Bone Marrow Metastasis, Disseminated Intravascular Coagulation","enrollment":24},{"nctId":"NCT03698461","phase":"PHASE2","title":"Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2019-05-15","conditions":"Colorectal Neoplasms, Neoplasm Metastasis, Colonic Neoplasms","enrollment":20},{"nctId":"NCT03291899","phase":"PHASE2","title":"Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract Cancers","status":"TERMINATED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2017-01-03","conditions":"Biliary Tract Cancer","enrollment":13},{"nctId":"NCT02928224","phase":"PHASE3","title":"Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-10-13","conditions":"BRAF V600E-mutant Metastatic Colorectal Cancer","enrollment":702},{"nctId":"NCT00551759","phase":"PHASE2","title":"Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer","status":"TERMINATED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2008-10-02","conditions":"Esophageal Cancer","enrollment":22},{"nctId":"NCT03437200","phase":"PHASE2","title":"Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2019-01-17","conditions":"Inoperable œsophageal Cancer","enrollment":8},{"nctId":"NCT05721872","phase":"PHASE1, PHASE2","title":"Efficacy, Tolerability and Safety of Intravenous D-VC With ATO in Patients With Advanced/Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Nazarbayev University","startDate":"2023-02-15","conditions":"Colorectal Cancer, Metastatic Colorectal Cancer","enrollment":38},{"nctId":"NCT02218164","phase":"PHASE2","title":"Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2014-08-12","conditions":"Squamous Cell Carcinoma of Skin, Carcinoma, Squamous Cell","enrollment":8},{"nctId":"NCT04480190","phase":"PHASE1","title":"Neoadjuvant Therapy in Biliary Adenocarcinoma","status":"WITHDRAWN","sponsor":"Jordan Kharofa","startDate":"2021-02-04","conditions":"Cholangiocarcinoma, Biliary Cancer","enrollment":""},{"nctId":"NCT01896531","phase":"PHASE2","title":"A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2013-08-14","conditions":"Gastric Cancer","enrollment":153},{"nctId":"NCT05194878","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-12-01","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":840},{"nctId":"NCT00193219","phase":"PHASE2","title":"Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2005-07","conditions":"Colon Cancer","enrollment":36},{"nctId":"NCT04418895","phase":"PHASE2","title":"Neoadjuvant Therapy for Localized Rectal Adenocarcinoma","status":"WITHDRAWN","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2021-08-13","conditions":"Rectal Adenocarcinoma","enrollment":""},{"nctId":"NCT02414009","phase":"PHASE2","title":"Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients","status":"COMPLETED","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2014-09","conditions":"Metastatic Colorectal Cancer","enrollment":82},{"nctId":"NCT02270606","phase":"PHASE1","title":"Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2014-12-04","conditions":"Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Rectum","enrollment":14},{"nctId":"NCT02715531","phase":"PHASE1","title":"A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-04-06","conditions":"Solid Tumor","enrollment":243},{"nctId":"NCT03536182","phase":"PHASE3","title":"Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2019-05-29","conditions":"Locally Advanced Pancreatic Adenocarcinoma","enrollment":""},{"nctId":"NCT02448810","phase":"PHASE2","title":"Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Baxalta now part of Shire","startDate":"2015-06-15","conditions":"Metastatic Colorectal Cancer","enrollment":115},{"nctId":"NCT01839799","phase":"PHASE2","title":"A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2013-04","conditions":"Pancreatic Adenocarcinoma","enrollment":32},{"nctId":"NCT04680104","phase":"","title":"Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination With 5-Fluorouracil (5FU) /or in FOLFIRI Regimen","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2015-11-03","conditions":"Gastrointestinal Cancer, CALCIUM LEVOFOLINATO (Ca-lev), SODIUM LEVOFOLINATO (Na-lev)","enrollment":64},{"nctId":"NCT01500993","phase":"PHASE3","title":"Capecitabine in the Perioperative Treatment of Rectal Cancer","status":"COMPLETED","sponsor":"Universitätsmedizin Mannheim","startDate":"2002-03","conditions":"Rectal Cancer","enrollment":401},{"nctId":"NCT02896803","phase":"PHASE2","title":"Fluorouracil and Oxaliplatin as First-line for Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2016-08","conditions":"Pancreatic Neoplasms","enrollment":37},{"nctId":"NCT00525785","phase":"PHASE2","title":"Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-01","conditions":"Stomach Cancer, Gastric Cancer","enrollment":58},{"nctId":"NCT00508404","phase":"PHASE2","title":"Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-05-09","conditions":"Metastatic Colorectal Cancer","enrollment":154},{"nctId":"NCT03788226","phase":"PHASE3","title":"A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2019-02-01","conditions":"Gastric Cancer Stage III","enrollment":600},{"nctId":"NCT00096278","phase":"PHASE3","title":"Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-09-15","conditions":"Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7","enrollment":2710},{"nctId":"NCT01183494","phase":"PHASE1","title":"A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2009-12-12","conditions":"Metastatic Colorectal Cancer","enrollment":17},{"nctId":"NCT00252564","phase":"PHASE3","title":"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"US Oncology Research","startDate":"2005-09","conditions":"Metastatic Colorectal Cancer","enrollment":247},{"nctId":"NCT01996306","phase":"PHASE3","title":"A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC","status":"COMPLETED","sponsor":"Epidemiological and Clinical Research Information Network","startDate":"2013-12-02","conditions":"Colorectal Neoplasms, Neoplasm Metastasis, Intestinal Neoplasms","enrollment":650},{"nctId":"NCT02919878","phase":"PHASE2","title":"Neo-adjuvant Chemoradiotherapy Using Infusional Gemcitabine Followed by Surgery for Locally Advanced Rectal Cancer","status":"UNKNOWN","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2014-12","conditions":"Rectal Adenocarcinoma","enrollment":25},{"nctId":"NCT03401957","phase":"","title":"The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment","status":"UNKNOWN","sponsor":"National Health Research Institutes, Taiwan","startDate":"2018-01","conditions":"Colorectal Cancer, Drug Resistance, Mass Spectrometry","enrollment":120},{"nctId":"NCT00463840","phase":"PHASE1, PHASE2","title":"Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2004-06","conditions":"Pancreatic Cancer","enrollment":24},{"nctId":"NCT03303495","phase":"PHASE3","title":"A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2011-11-14","conditions":"Colorectal Neoplasms, Neoplasm Metastasis, Intestinal Neoplasms","enrollment":280},{"nctId":"NCT00188266","phase":"PHASE1, PHASE2","title":"Study of Adjuvant Radiochemotherapy for Gastric Cancer","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2002-08","conditions":"Stomach Neoplasms","enrollment":65},{"nctId":"NCT00948688","phase":"PHASE1, PHASE2","title":"Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2009-08","conditions":"Pancreatic Cancer, Adenocarcinoma of the Pancreas","enrollment":10},{"nctId":"NCT01047293","phase":"PHASE1, PHASE2","title":"RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma","status":"COMPLETED","sponsor":"University of Utah","startDate":"2010-05","conditions":"Colorectal Cancer","enrollment":47},{"nctId":"NCT01661114","phase":"PHASE2","title":"A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2011-07","conditions":"Pancreatic Cancer, Biliary Cancer","enrollment":39},{"nctId":"NCT01376453","phase":"PHASE1","title":"Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2011-06","conditions":"Rectal Cancer","enrollment":18},{"nctId":"NCT00332163","phase":"PHASE2","title":"Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-04","conditions":"Metastatic Colorectal Cancer, Skin Rash, Skin Toxicities","enrollment":95},{"nctId":"NCT00411450","phase":"PHASE2","title":"Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-11","conditions":"Colon Cancer, Colorectal Cancer, Rectal Cancer","enrollment":116},{"nctId":"NCT00462501","phase":"NA","title":"Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-03","conditions":"Colorectal Cancer","enrollment":35},{"nctId":"NCT01675999","phase":"PHASE2","title":"Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-05","conditions":"Colon Cancer, Locally Advanced Malignant Neoplasm","enrollment":186},{"nctId":"NCT00851045","phase":"PHASE2","title":"Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-10","conditions":"Colorectal Cancer (CRC)","enrollment":17},{"nctId":"NCT00417976","phase":"PHASE2","title":"Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer","status":"COMPLETED","sponsor":"Tony Bekaii-Saab","startDate":"2006-12","conditions":"Pancreatic Cancer","enrollment":42},{"nctId":"NCT01238965","phase":"PHASE1","title":"Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2010-10","conditions":"Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer","enrollment":7},{"nctId":"NCT00042861","phase":"PHASE1","title":"UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-08","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT01219920","phase":"PHASE3","title":"FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2001-11","conditions":"Metastatic Colorectal Cancer","enrollment":244},{"nctId":"NCT01163396","phase":"PHASE2","title":"First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2007-07","conditions":"Colorectal Cancer Metastatic","enrollment":57},{"nctId":"NCT00646607","phase":"PHASE3","title":"FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer","status":"COMPLETED","sponsor":"Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente","startDate":"2007-06","conditions":"Colon Cancer","enrollment":3756},{"nctId":"NCT01238939","phase":"PHASE1","title":"Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer","status":"COMPLETED","sponsor":"Nippon Kayaku Co., Ltd.","startDate":"2010-08","conditions":"Advanced Solid Tumors, Metastatic Colorectal Cancer","enrollment":35},{"nctId":"NCT00336141","phase":"PHASE1","title":"Vorinostat and IV Fluorouracil/Leucovorin (5FU/LV) in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2006-06","conditions":"Colorectal Cancer","enrollment":10},{"nctId":"NCT00111761","phase":"PHASE2","title":"Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-07","conditions":"Colorectal Cancer","enrollment":43},{"nctId":"NCT00004150","phase":"PHASE3","title":"High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer","status":"COMPLETED","sponsor":"Robert Roessle Klinik","startDate":"1999-03","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT00123318","phase":"PHASE3","title":"A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer","status":"COMPLETED","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2003-02","conditions":"Gastric Cancer","enrollment":52},{"nctId":"NCT00002470","phase":"PHASE2","title":"Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors","status":"COMPLETED","sponsor":"Mid-Atlantic Oncology Program","startDate":"1990-09","conditions":"Gastrointestinal Carcinoid Tumor, Lung Cancer","enrollment":""},{"nctId":"NCT00002593","phase":"PHASE3","title":"S9415 Chemotherapy in Patients With Stage II or III Colon Cancer That Has Been Surgically Removed","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1994-12","conditions":"Colorectal Cancer","enrollment":1135},{"nctId":"NCT00003018","phase":"PHASE2","title":"S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1997-09","conditions":"Pancreatic Cancer","enrollment":54},{"nctId":"NCT00052962","phase":"PHASE3","title":"Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-01","conditions":"Gastrointestinal Neoplasm","enrollment":30},{"nctId":"NCT00064181","phase":"PHASE3","title":"Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2003-05","conditions":"Colorectal Cancer","enrollment":86},{"nctId":"NCT00026273","phase":"PHASE3","title":"Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2001-01","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT00003287","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1998-03","conditions":"Colorectal Cancer","enrollment":554},{"nctId":"NCT00003029","phase":"PHASE3","title":"Fluorouracil With or Without Cisplatin in Treating Patients With Advanced or Metastatic Cancer of the Pancreas","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1997-05","conditions":"Pancreatic Cancer","enrollment":200},{"nctId":"NCT00019513","phase":"PHASE1","title":"Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"1998-08","conditions":"Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer","enrollment":108},{"nctId":"NCT00786643","phase":"PHASE2","title":"Study of Gamma Interfereon in Metastatic Colorectal Carcinoma","status":"COMPLETED","sponsor":"Accelerated Community Oncology Research Network","startDate":"2006-02","conditions":"Colorectal Cancer","enrollment":48},{"nctId":"NCT01088581","phase":"PHASE3","title":"Adjuvant Hepatic Arterial Infusional Chemotherapy After Curative Resection of Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2006-01","conditions":"Hepatocellular Carcinoma","enrollment":101},{"nctId":"NCT00291785","phase":"PHASE1, PHASE2","title":"Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2004-01","conditions":"Colorectal Cancer","enrollment":48},{"nctId":"NCT00193141","phase":"PHASE2","title":"Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"1999-10","conditions":"Esophagus Cancer","enrollment":200},{"nctId":"NCT00143403","phase":"PHASE3","title":"Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2001-12","conditions":"Colorectal Neoplasms, Liver Neoplasms","enrollment":321},{"nctId":"NCT00106054","phase":"PHASE2","title":"Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases","status":"TERMINATED","sponsor":"Pfizer","startDate":"2006-01","conditions":"Colorectal Neoplasms, Liver Neoplasms","enrollment":2},{"nctId":"NCT00101686","phase":"PHASE3","title":"Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-02","conditions":"Colorectal Neoplasms","enrollment":547},{"nctId":"NCT00619541","phase":"PHASE2","title":"Study of Sorafenib and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma (HCC)","status":"COMPLETED","sponsor":"Italian Trial in Medical Oncology","startDate":"2007-01","conditions":"Hepatocellular Carcinoma","enrollment":46},{"nctId":"NCT00509964","phase":"PHASE2","title":"Second-Line Irinotecan vs. ILF for AGC","status":"UNKNOWN","sponsor":"Gachon University Gil Medical Center","startDate":"2007-05","conditions":"Stomach Neoplasm, Metastatic, Second-Line","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":469,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Adrucil","Efudex","Fluoroplex"],"phase":"phase_2","status":"active","brandName":"Infusional 5-Fluorouracil","genericName":"Infusional 5-Fluorouracil","companyName":"Italian Trial in Medical Oncology","companyId":"italian-trial-in-medical-oncology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Infusional 5-Fluorouracil is used to treat various types of cancer, including colorectal cancer, gastroesophageal junction adenocarcinoma, colon cancer, stomach neoplasm, and metastatic cancer. It works by inhibiting the enzyme thymidylate synthase, which is involved in DNA synthesis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}